Jason Kralic

Co-founder and CEO @Tellus Therapeutics, Inc

Raleigh-Durham-Chapel Hill, NC, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Oct 2018 — Present

Co-founder and CEO @Tellus Therapeutics, Inc

View department →

Durham, NC, US

Tellus Therapeutics is developing novel small molecules derived from human maternal breast milk for the treatment of newborns with perinatal brain injury. Tellus\' lead candidate, TT-20, induces regeneration of myelin-producing oligodendrocytes, reverses white matter injury in an animal model of perinatal brain injury and multiple sclerosis and is pursuing a novel regulatory path to evaluate safety and efficacy in newborns with brain injury.

EDUCATION

1997 — 2002

UNC School of Medicine

PhD, Pharmacology/Neuroscience

1993 — 1997

Ohio Wesleyan University

BA, Biochemistry

SKILLS

ImmunologyAssay DevelopmentGlpStrategyMedical DevicesTranslational ResearchDrug DeliveryLicensingCROCommercializationOncologyChemistryRegulatory AffairsLifesciencesPharmacologyVaccinesRegulatory SubmissionsProtein ChemistryIn VivoCRO ManagementPharmaceutical IndustryClinical DevelopmentNeuroscienceLife SciencesCellTranslational MedicineMolecular BiologyTechnology TransferBiomarkersBiotechnologyResearch and Development (R&D)Drug DevelopmentBiopharmaceuticalsDrug DiscoveryR&DBiochemistryInfectious DiseasesBusiness DevelopmentClinical TrialsIn Vitro

ABOUT JASON KRALIC

Jason Kralic, Ph.D. is a neuropharmacologist and BD professional with broad experience in technology innovation, R&D, licensing and company creation. Jason co-founded Tellus Therapeutics with Duke neonatologist and stem cell biologist, Eric Benner, MD/PhD, focused on the development of treatments for neonatal brain injury. Jason founded Innervate BD Solutions in 2015, an advisory firm helping clients realize the full potential of their science and business through planning and execution of objective-driven strategies.Jason was previously Associate Vice President of Technology Innovation at Wake Forest Baptist Medical Center where he facilitated the evaluation, protection, development and licensing of therapeutics, medical devices, diagnostics and digital health technologies aimed at improving human health. Prior to Wake Forest Innovations, Jason was Vice President of Business Development at Opexa Therapeutics and Head of Business Development for Neurosciences R&D at GlaxoSmithKline responsible for setting the BD strategy, leading licensing and M&A activities and facilitating relationships with alliance partners. Jason has also served in scientific licensing roles at UCB Pharma and Schwarz Biosciences. Jason holds a Ph.D. in pharmacology from the University of North Carolina at Chapel Hill and completed post-doctoral training at the University of Zurich. Throughout his career, Jason has been a strong advocate for STEM education and growth of biotechnology in North Carolina.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Jason Kralic — Co-founder and CEO at Tellus Therapeutics, Inc in Raleigh-Durham-Chapel Hill, NC, US | Unifers